Form 4: Theravance Biopharma CEO Acquires Shares Under Equity Incentive Plan

Theravance Biopharma's CEO, Rick E. Winningham, acquired 3,252 ordinary shares at $7.83 per share under the company's Amended and Restated 2013 Equity Incentive Plan.

Summary

• On August 7, 2024, Rick E. Winningham, CEO of Theravance Biopharma, acquired 3,252 ordinary shares of the company.
• The shares were acquired at a price of $7.83 per share.
• The acquisition was made pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan.
• Following the transaction, Winningham directly owns 1,839,896 ordinary shares.
• Winningham also indirectly owns 3,900 ordinary shares as custodian and 92,567 ordinary shares by trust.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, and the transaction itself is neither particularly positive nor negative. It reflects standard executive compensation practices.

Positives

• The CEO's acquisition of shares may signal confidence in the company's future prospects.
• The transaction occurred under a pre-existing equity incentive plan, suggesting a structured and planned approach to executive compensation.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. This transaction is a routine disclosure of insider activity.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves a relatively small number of shares compared to the total outstanding shares.
• The transaction is part of the executive compensation plan, which is of interest to employees.

Key Dates